Comparative Patent Case Studies: India Vs Us.
1. Novartis AG v. Union of India (India, 2013)
Facts:
Novartis applied for a patent for the cancer drug Glivec, claiming it was an improved version of a known compound. Indian Patent Office rejected it under Section 3(d), which bars patents for minor modifications of known drugs unless they show enhanced efficacy.
Legal Issues:
Patentability of incremental innovations.
Section 3(d) and its interpretation.
Balancing public interest with innovation incentives.
Outcome:
Supreme Court of India upheld the rejection, emphasizing that Glivec did not show significant therapeutic efficacy over the known drug.
Novartis lost its patent claim in India.
UK Comparison:
In the UK, the equivalent case might have been evaluated under the “inventive step” and “non-obviousness” standards.
The UK would likely grant a patent if a new form shows improved properties unless it’s considered obvious to a skilled person.
India’s law is stricter for pharmaceuticals due to public health concerns.
Significance:
Highlights India’s public health-oriented patent regime, contrasting with the UK’s innovation-focused approach.
2. Bayer Corporation v. Union of India (India, 2016)
Facts:
Bayer sought patent protection for Nexavar, a cancer drug. Indian courts questioned the efficacy claims and whether it was a new invention under Section 3(d).
Legal Issues:
Patentability of life-saving drugs in India.
Compulsory licensing and access to medicine.
Outcome:
Indian courts allowed a generic manufacturer (Natco Pharma) to produce Nexavar under compulsory license due to high cost and public health needs.
Bayer retained patents but could not prevent generic production.
UK Comparison:
In the UK, compulsory licensing is very rare; Bayer would have likely maintained exclusive rights.
UK law emphasizes patent rights over public access, unless a voluntary license is negotiated.
Significance:
Demonstrates the strong public-interest approach in India versus the patent-holder-friendly approach in the UK.
3. Roche Products Ltd. v. Cipla Ltd. (India, 2015)
Facts:
Roche sued Cipla for selling a generic version of Tarceva (cancer drug) in India. Cipla claimed the patent was invalid under Section 3(d) as the drug was a minor modification.
Legal Issues:
Incremental innovation vs. patentability.
Section 3(d) enforcement for generics.
Outcome:
Indian courts largely favored Cipla, allowing generic production.
Roche’s patent was challenged based on lack of enhanced efficacy.
UK Comparison:
In the UK, Roche would have stronger protection unless the invention was obvious or lacked inventive step.
Indian law imposes additional hurdles for pharmaceutical patents.
Significance:
Shows the unique Indian restriction on minor modifications, which is absent in the UK patent system.
4. Actavis UK Ltd. v. Eli Lilly and Company (UK, 2012)
Facts:
Eli Lilly sued Actavis for infringement of its cancer drug patent (Alimta) in the UK. Actavis argued “purposive construction”, challenging the scope of the patent claims.
Legal Issues:
Claim interpretation in UK patent law.
Doctrine of equivalents vs. strict literal infringement.
Outcome:
UK Supreme Court applied a purposive construction test: if Actavis’ product performs substantially the same function in substantially the same way, it infringes.
Actavis lost the infringement claim.
India Comparison:
India relies more on literal infringement and Section 3(d) standards.
Indian courts might not have considered minor modifications as infringement if no new efficacy was demonstrated.
Significance:
Highlights the more flexible approach to claim interpretation in the UK versus India’s restrictive, public-health-focused approach.
5. Monsanto Technology LLC v. Nuziveedu Seeds Ltd. (India, 2018)
Facts:
Monsanto sued Indian seed companies for infringing patents on genetically modified Bt cotton seeds.
Legal Issues:
Patentability of genetically modified seeds.
Enforcement against farmers and seed companies.
Outcome:
Indian courts ruled in favor of Monsanto in some cases, but restricted enforcement against small farmers to protect livelihood.
Compensation was primarily targeted at large commercial seed sellers.
UK Comparison:
In the UK, Monsanto would likely be able to enforce patents strictly, with no carve-out for farmers.
Significance:
Shows India’s socio-economic consideration in patent enforcement, which is largely absent in UK law.
6. Generics (UK) Ltd. v. Teva Pharmaceuticals (UK, 2010)
Facts:
Generics challenged Teva’s patent on a pharmaceutical compound. The dispute focused on validity and obviousness of the claimed invention.
Legal Issues:
Obviousness standard in UK law (section 3 of the UK Patents Act).
Evidence-based approach to inventive step.
Outcome:
UK courts invalidated Teva’s patent for lack of inventive step.
The generic company was allowed to market the drug.
India Comparison:
India also uses inventive step as a criterion, but combined with enhanced efficacy requirement for pharmaceuticals.
More patents are rejected in India due to Section 3(d) than in the UK.
Significance:
Highlights the UK’s purely technical evaluation versus India’s additional social/public health filter.
7. GlaxoSmithKline v. Novartis (UK, 2013)
Facts:
Dispute over patenting combination drugs for HIV treatment.
Legal Issues:
Inventive step and novelty.
Combination patent scope in UK law.
Outcome:
UK courts favored GSK, granting patent protection as the combination offered clear technical advantages.
India Comparison:
India would also examine enhanced efficacy, so a combination drug must show significant therapeutic improvement.
A minor combination without enhanced efficacy could be rejected.
Significance:
Illustrates India’s higher bar for pharmaceutical patents, while the UK prioritizes technical innovation.
Key Comparative Insights: India vs UK Patent Law
| Aspect | India | UK |
|---|---|---|
| Pharmaceutical Patents | Must show enhanced efficacy (Section 3(d)) | Focus on inventive step & non-obviousness |
| Public Health Considerations | Strong; compulsory licensing possible | Weak; favors patent holder |
| Scope of Infringement | Literal interpretation; stricter limits | Flexible; purposive construction applied |
| Incremental Innovation | Often rejected if minor improvement | More likely accepted if non-obvious |
| Socio-Economic Factors | Enforcement may limit impact on farmers/public | Enforcement strictly protects patent rights |
| Parallel Enforcement | Public interest often limits exclusivity | Patent holder enjoys broader exclusive rights |
RELATED Blog
comments